Publications

Best practices for delivering neoadjuvant therapy in pancreatic ductal adenocarcinoma

JM Cloyd, A Sarna, MJ Arango, SE Bates, MS Bhutani, M Bloomston, ...

Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.

PA Cassier, JL Van Laethem, I Borbath, T Macarulla, KP Geboes, ...

Blood sample collection in randomized controlled trials for biomarker discovery and validation: experience of the PREOPANC-2 trial

EN Dekker, QP Janssen, JL van Dam, GJ Strijk, EMM Verkolf, S Kandala, ...

Body mass index and somatic variants in biliary tract cancers.

L Al Mahmasani, JF Chou, M Capanu, A Srivastava, CS Sigel, ...

Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration …

EN Dekker, D Van Klaveren, EMM Verkolf, RF De Wilde, MG Besselink, ...

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

JL Van Laethem, K Geboes, I Borbath, TM Mercade, A Lambert, P Cassier, ...

Characteristics of long-term survivors and impact of dose adjustments in first-line NALIRIFOX treatment for metastatic pancreatic ductal adenocarcinoma: post hoc analyses of …

V Chung, A Patel, Y Liu, M Kochenderfer, N Natarajan, GR Williams, ...

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

R Thummalapalli, M Darmofal, K Seier, DN Khalil, HS Walch, J Shia, ...

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer

Cowzer D, Darmofal M, Seier K, Thummalapalli R, Walch H, El Dika I, Khalil DN, Park W, et al.

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

Clinico-genomic characterization of PALB2-mutated pancreatic adenocarcinoma.

JW Lee, CA O'Connor, E Harrold, AL Richards, F Velez-Cortes, D Moss, ...

Clinicogenomic comparison of patients with liver-avid/lung-adverse and lung-avid/liver-adverse patterns of metastases highlights commonalities across cancer types

J Nguyen, WK Chatila, P Manca, H Walch, S Nandakumar, P Razavi, ...

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Clinicopathologic and allele-specific analysis of germline ATM alterations in a pan-cancer cohort.

M Repetto, D Muldoon, P Selenica, K Arora, YL Liu, M Carlo, L Banaszak, ...

Complementary Chinese Herbal Medicine Use and Gastrointestinal Cancers: A Scoping Review of Usage Patterns and Survival Outcomes in Taiwanese Population-Based Studies

CS Lam, E Kwag, S Chimonas, SL Cytryn, YN Hou, HR Yen, ED Kantor, ...

DESCRIBING HEMATOLOGICAL ADVERSE EVENTS (AES) AND UTILIZATION OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) AMONG PATIENTS RECEIVING NALIRIFOX FOR METASTATIC PANCREATIC …

K Sampat, M Cusnir, P Cockrum, A Sosinksy, AM Siney, E O'Reilly

Early-Phase Trials in Journal of Clinical Oncology

Stinchcombe TE, Fleming GF, Craddock C, Ko AH, O'Reilly EM, Maki RG

Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3.

AJ Patel, AA Laursen, P Cockrum, Y Liu, A Surinach, W Rhodes, L Zhang, ...

Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET …

JR Strosberg, TJ Zemla, SM Geyer, MV Knopp, S Behr, S Pulsipher, ...

Efficacy of zenocutuzumab in NRG1 fusion-positive cancer

AM Schram, K Goto, DW Kim, T Macarulla, A Hollebecque, EM O’Reilly, ...

Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC …

EM O’Reilly, T Macarulla, L Dahan, I Borbath, PA Cassier, F Guelfucci, ...

Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2

S Lucotti, Y Ogitani, CM Kenific, J Geri, YH Kim, J Gu, U Balaji, L Bojmar, ...

Feasibility of Endoscopic Ultrasound-Guided Tissue Acquisition for Next-Generation Sequencing in Pancreatic Cancer Patients

SE Lee, D Kim, N Zbib, C Sigel, E Vakiani, EM O'reilly, K Yu, W Jarnagin, ...

Fecal Immunochemical Tests (FIT) and Focus Groups: Tailoring Bilingual Cancer Screening Education

Haveric A, Balogun F, Gilliland J, Narang B, Gany F

First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer

Nasca V, Tinè G, Taieb J, Lonardi S, Boursi B, Margalit O, Salvatore L, Cohen R, et al.

Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors.

CA McIntyre, V Rudneva, AL Richards, W Park, WR Jarnagin, ...

Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation

Chiang CH, Song J, Chang YC, Osataphan S, Lee YC, Chang KY, Chi KY, Chiang CH, et al.

Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET …

AC Dueck, B Fruth, SM Geyer, T Zemla, S Pulsipher, FS Ou, JD Acoba, ...

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel+ gemcitabine in treatment-naive patients with metastatic pancreatic ductal …

D Melisi, T Macarulla, C De La Fouchardiere, RAP Cid, SR Chandana, ...

Hepatic artery infusional chemotherapy for unresectable intrahepatic cholangiocarcinoma

R Alessandris, M Rousian, L Schleimer, H Kalvin, A Cercek, L Connell, ...

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy

E O’Reilly, E Johal, H Clark, B Mou, RE Cereno, M Liu, D Schellenberg, ...

Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer

Schleimer LE, Aviki E, Kalvin HL, Magnin J, Sokolowski SS, Kingham TP, O'Reilly EM, Varghese AM, et al.

Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3.

M Abdelrahim, G Khan, H Hatoum, A Zervoudakis, F Dayyani, L Zhang, ...

Indian Consensus Guidelines for the Management of Pancreatic Cancer

V Lavingia, S Gohel, S Shrikhande, SK Mullapally, A Ramaswamy, ...

Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma

Judge SJ, Manin E, Chou J, Torphy RJ, McIntyre CA, Balachandran VP, D'Angelica MI, Drebin JA, et al.

International Fibrolamellar Cancer Registry: Opportunities and Challenges

Al Mahmasani L, Capanu M, Losert K, Chou JF, Lowery MA, Hennessy M, Ray M, Chambers S, et al.

Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival

Chandra P, Song Y, Drill E, Wei AC, Kemeny N, Cercek A, Connell L, Harding J, et al.

Longitudinal imaging markers for pancreas cancer tumor response via Eshelby biomechanics

JS Heiselman, N Horvat, M El Homsi, BL Ecker, EM O’Reilly, TP Kingham, ...

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, et al.

Maximal Ablative Irradiation Because of Encasement for Patients with Potentially Resectable Locally Advanced Pancreatic Cancer: Final Results of Phase II MAIBE Trial

M Reyngold, A Wei, C Hajj, M Zinovoy, W Jarnagin, MI D'Angelica, ...

Mechanisms of resistance to the RAS (ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS (ON) combination therapies

S Kar, Y Zhuang, E Ahler, LP Lai, A Starodub, A Spira, SR Punekar, ...

Metastatic Epstein-Barr Virus-Associated Lymphoepithelioma-Like Carcinoma of Small Bowel Origin

JJ Tao, H Hibshoosh, SM Lagana, F Balogun, RA White

Mitigation of gastrointestinal (GI) side effects among patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma (mPDAC)

P Patel, A Laursen, C Lieb, F Maxwell, E O'Reilly, AM Siney

Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS …

D Cowzer, HS Walch, P Atri, F Shah, R Huq, DN Khalil, W Park, R Yeh, ...

Molecular differences in pancreatic ductal adenocarcinomas from black versus white patients

S Mandal, EA Teslow, M Huang, Y Yu, S Sridhar, HC Crawford, ...

MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors.

NJ Lakhani, D Melisi, V Subbiah, NR Ammakkanavar, EM O'Reilly, ...

Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hypofractionated Offline Adapted Radiation Therapy for Locally Advanced Pancreatic Cancer

Chuong MD, O'Reilly EM, Herrera RA, Zinovoy M, Mittauer KE, Rubens M, Kaiser A, Romesser PB, et al.

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the …

V Chung, MD Kochenderfer, N Natarajan, GR Williams, AA Laursen, ...

Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma

GK Abou-Alfa, T Meyer, RKG Do, SA Piha-Paul, JS Light, S Sherrin, ...

Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy

Reyngold M, Schoenfeld JD, O'Reilly EM, Varghese AM, White C, Zinovoy M, Romesser PB, Wu AJ, et al.